Excerpts from latest analyst reports

Maybank KE maintains 'buy' call on Midas

Analyst: Wei Bin

Patrick Chew, CEO, Midas Holdings. Photo: Company

Following a meeting with management recently, we believe that Midas is on track for recovery in the medium term once it overcomes the lingering difficulties that will persist in the next few quarters.

Potential contract wins from upstream customers such as CSR and CNR, China’s two largest train makers, will help restore the company’s profit back to a more normal level. Midas has also been working hard to diversify its revenue base, including moving up the value chain into the fabrication business, strengthening its foothold in the power industry and venturing further overseas.

Though such diversification and building of new factories will eat into margins in the short term, they will ensure Midas’s sustainability in the long term.

More years to go for China’s high-speed rail. As far as we know, there are no major changes to China’s original plan to build 16,000km of high-speed rail lines by 2020. The fatal railway accident and corruption scandal in 2011 put a spanner in the works and only about half of the targeted length has been completed so far. This means a reacceleration of construction is possible in the next few years.

Expect earnings recovery from 2H13. Assuming the Ministry of Railways issues a new round of high-speed train tenders early next year, we expect Midas may be able to record earnings recovery in 2H13 or 1H14, give and take six months for delivery. In our view, Midas’s current share price will be supported by 0.8x FY13F P/BV. Maintain BUY and TP of SGD0.48.

Recent story: Kevin Scully: Another positive development for MIDAS


Barclays initiates coverage of Biosensors with 'overweight' and $1.50 target

Analyst: Jason Mann, M.D., Ph.D.

Biosensor's drug-eluting stent is used by surgeons to treat diseased coronary arteries. Image: company

We initiate coverage of Biosensors with an Overweight rating and PT of S$1.50. We recommend this stock for three reasons:

1) the company's leading position in China's coronary stent market (20% revenue market share) with expansion in other emerging markets (>20% y/y revenue growth), driving base case revenue/net income CAGRs of 15%/17% in FY12-15E;

2) strong R&D offering true innovation, which we expect to sustain the company's competitive advantage and protect margins; and

3) compelling valuation at 13x FY13E P/E (10x ex-cash), a 25% discount to medical device peers.

We see downside support from the share buyback programme and solid balance sheet (25% of market cap in cash).

Management is actively pursuing M&A and we see its early bond repayment (one month early in November 2012) as providing it with more flexibility for M&A, which adds potential upside risk to our estimates.

Recent story: DMX, SINO GRANDNESS, BIOSENSORS: More than 50% upside?

Share Prices

Counter NameLastChange
AEM Holdings3.8700.030
Avi-Tech Electronics0.2800.005
Best World1.7900.030
Broadway Ind0.118-
China Sunsine0.405-
Food Empire0.635-0.015
Fortress Minerals0.330-
Geo Energy Res0.360-0.015
Golden Energy0.7850.005
GSS Energy0.0480.002
ISDN Holdings0.4150.010
IX Biopharma0.1270.001
Jiutian Chemical0.0820.004
KSH Holdings0.350-
Leader Env0.056-
Medtecs Intl0.139-0.001
Meta Health0.025-
Nordic Group0.475-0.005
Oxley Holdings0.1500.001
REX International0.2400.005
Sinostar PEC0.1850.015
Southern Alliance Mining0.380-
Straco Corp.0.400-0.005
Sunpower Group0.2850.025
The Trendlines0.0930.005
Totm Technologies0.103-0.002
UG Healthcare0.194-0.001
Uni-Asia Group0.8350.005
Wilmar Intl4.120-
Yangzijiang Shipbldg1.410-0.010

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 2219 guests and no members online